See also this year's filing and all EDGAR filings for this company.
PDF Report 0001267813_2023_MARINUS_PHARMACEUTICALS_INC.pdf
Logs
| warning | Large missing amount for aggregate "Revenues" added to remainder. | industry.us_generic | {'missing_ratio': 2.673828406633021, 'aggregate_val': 25478000, 'exp_sum': 6935000, 'exp_to_value': {'remainder_Revenues': 6935000}} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.0022370334304907657, 'aggregate_val': 152327000, 'exp_sum': 151987000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 56845000, 'ResearchAndDevelopmentExpense': 79912000, 'remainder_Expenses': 15230000}} |
Graph
Absolute values for 0001267813, MARINUS PHARMACEUTICALS INC.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 252,378,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 4,236,000 |
| 3 | remainder_Assets | 2,904,000 |
| 4 | LiabilitiesCurrent | 25,017,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 118,501,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 56,845,000 |
| 9 | ResearchAndDevelopmentExpense | 79,912,000 |
| 10 | remainder_Expenses | 15,570,000 |
| 11 | remainder_Revenues | 25,478,000 |
| 12 | remainder_NetIncome | 107,033,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 259,518,000 |
| 1 | Liabilities | 143,518,000 |
| 2 | Expenses | 152,327,000 |
| 3 | Revenues | 25,478,000 |
| 4 | StockholdersEquity | 116,000,000 |
| 5 | NetIncome | -19,816,000 |
| 6 | ComprehensiveNetIncome | -19,816,000 |
| 7 | BaseVar | 343,937,000 |
| 8 | EconomicCapitalRatio | 0.892 |
Edgar->Model Mapping
Feature Distribution
Change over Time
